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EDITORIAL COMMENT
Genomic Medicine
and Atrial Fibrillation*
Luisa Mestroni, MD, FACC, FESC
Denver, Colorado
Recent developments and improved understanding in
genomics (the interactions and functions of genes) have
profoundly changed the perspective of researchers and
medical practitioners toward diseases that had previously
been associated with environmental factors alone (1). It is
now widely recognized that many common disorders, such
as heart disease, cancer, infections, Parkinson’s disease, and
Alzheimer’s disease, are rooted in environmental factors as
well as in genetic variation. Recent research strongly sup-
ports the concept that defective genes and/or gene variation
plays a much larger role in the development of certain
disorders than was previously suspected.
See page 2185
Epidemiology and clinical implications of atrial fibrilla-
tion. Atrial fibrillation (AF) is a common disorder that is
proving to be an excellent example of the interaction
between environmental and genetic factors. Atrial fibrilla-
tion is one of the primary causes of mortality, morbidity,
and socioeconomic consequences from hospitalizations.
Atrial fibrillation is characterized by a rapid and irregular
activation of the atrial myocardium at a rate of approxi-
mately 400 to 600 pulses/min. The uncontrolled rapid
ventricular response rate may eventually cause ventricular
dysfunction and heart failure. Additionally, the loss of
effective atrial contraction may also cause blood stasis and
promote the occurrence of thromboemboli and stroke. As a
result, AF requires long-term anticoagulant and rate-
control therapy, and sometimes more sophisticated treat-
ments, such as ablation and implantable devices.
Atrial fibrillation and atrial flutter account for approxi-
mately 9,000 deaths and 400,000 hospitalizations annually,
and they are the cause of stroke in about 15% of patients (2).
The prevalence of AF is estimated to be between 0.5 and 1%
in the general population, and the condition affects approx-
imately 2.2 million individuals in the U.S. alone (3). The
incidence and prevalence of AF increases with age: approx-
imately 70% of those diagnosed with AF are between 65
and 85 years old (3). Braunwald (4) has recently described
AF as a growing “epidemic” as the population of elderly
continues to increase. Still, the real frequency of AF is
probably underestimated (5) because of the high rate (30%
to 45%) of asymptomatic arrhythmia, which frequently goes
undetected.
In spite of AF’s clinical relevance, the origin and the
mechanisms underlying this common arrhythmia have, until
recently, been obscure. Atrial fibrillation has been recog-
nized since the early 1900s and typically has been associated
with conditions that increase atrial pressure or cause atrial
dilation (Table 1). Atrial fibrillation is also associated with
cardiomyopathies (6–10), diseases of the cardiac muscle
which are known to be genetically determined in a large
proportion of patients. Finally, AF may also occur in
patients without any other evidence of heart or systemic
disease, a condition known as lone AF. Lone AF accounts
for 2% to 31% of the AF patient population (5) and usually
affects young and middle-aged adults.
Although very little was known about the molecular
determinants of AF until a few years ago, recent advances
have significantly improved our understanding of this con-
dition. These include new insights into the genetic basis of
the disease and the discovery of gene expression changes
that produce electrical and structural remodeling of the atria
during AF.
Genetic epidemiology of AF. The familial occurrence of
AF has been known for many decades yet traditionally has
been considered a rare event (5,11). However, the study of
the familial forms of AF caused by a gene defect was
considered key to the discovery of factors that constitute
initiation of AF.
The first important advance in this direction has been the
identification of a genetic locus for familial AF on chromo-
some 10q22-q24, by Brugada et al. (12). Three families
from Catalonia, Spain, were studied and showed an auto-
somal dominant pattern of transmission and early onset of
the arrhythmia (age 1 to 45 years). Positional cloning and
analysis of candidate genes to identify the disease gene are
currently ongoing. Since the beginning of their studies,
Brugada et al. (11) have collected probands from more than
100 families with familial AF. Their findings revealed that
not all families were affected by the chromosome 10q22-q24
locus, suggesting that familial AF is a genetically heteroge-
neous disorder caused by more than one gene. Their
findings also supported the notion that familial AF may be
more common than previously suspected.
In this issue of the Journal, Darbar et al. (13) report the
results of a large survey performed in the arrhythmia clinic
at the Mayo Clinic in Rochester, Minnesota. Out of 914
patients with AF, 36% had lone AF, and of that patient
population, 15% had a familial history of the disorder (5% of
the overall population). These findings discount the old idea
that familial AF is a rare condition. The age of onset in the
50 probands with familial AF ranged from 25 to 55 years.
The investigators were able to identify four multigenera-
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tion families that showed an autosomal dominant pattern of
transmission, as previously reported. Interestingly, none of
them showed linkage with the locus on chromosome 10 that
was reported in the families from Catalonia, suggesting the
existence of yet another gene or multiple genes.
The other intriguing feature was that different ventricular
responses and different outcomes were observed in the
phenotype analysis. In three families, the affected family
members had symptomatic AF with rapid ventricular re-
sponse, in some instances leading to tachycardia-induced
cardiomyopathy, which improved after sinus rhythm resto-
ration or rate-control. These families had also experienced a
significant incidence of stroke. On the other hand, affected
members of the fourth family frequently had asymptomatic
AF, with slow ventricular response, atrial myopathy, pro-
gression to conduction delay, and “ventricular” cardiomyop-
athy.
The two different phenotypes described in the study of
Darbar et al. (13) may indicate two distinct mechanisms
(and corresponding genes or pathways) involved in the
origin of AF. The phenotype with AF and slow ventricular
response suggests an underlying more diffuse myocardial
disease. Indeed, the coexistence of atrial arrhythmia (includ-
ing AF) and conduction defects are found in cardiomyop-
athies caused by mutations of cytoskeletal genes of the
nuclear lamina, such as emerin and lamin (Table 1) (6,14).
On the other hand, the phenotype with AF rapid ventricular
response and without primary involvement of the “working”
myocardium may suggest an ion channel disease, such as
cases of ventricular arrhythmia due to sodium channel
mutations (long QT syndrome, Brugada syndrome, or
idiopathic ventricular tachycardia) (14). Most recent ad-
vances in the molecular genetics of AF support this hypoth-
esis and are discussed later.
The attempt to define the epidemiology of familial AF by
Darbar et al. (13) has several limitations. These include the
possibility of a referral bias overestimating the frequency of
lone AF, an underestimate due to clinically silent forms, or
survey results based on family history rather than clinical
evaluation of relatives. Further, the relative frequency of the
rapid- and slow-ventricular rate AF in the overall popula-
tion is unknown. However, the relevant messages emerging
from this study are that the familial occurrence of AF is not
rare, that the condition is probably due to several different
genes and molecular mechanisms, that it may be associated
with young age and complications such as stroke and
cardiomyopathy, and that patients with this disorder should
undergo adequate screening, therapy, and counseling.
Role of gene mutations in the origin of AF. The hypoth-
esis that ion channels could have a major role in causing AF
has been recently confirmed by two studies. The first study
tested the hypothesis of an association between AF and a
genetic variation (polymorphism) in the minK gene
(KCNE1), encoding the beta subunit of the IKs potassium
channel (KvLQT1/minK) (15). The IKs potassium channel,
formed by the alpha (KvLQT1) and beta (minK) subunits,
determines the “slow” component of the K current, causing
cellular depolarization in atrial myocardium. In a Chinese
population with risk factors for AF (including valvular heart
disease, hypertension, and left ventricular dysfunction),
patients with the 38G allele were more likely to develop AF
than patients with the 38S allele. Unfortunately, the func-
Table 1. Genotype/Phenotype Correlations in Atrial Fibrillation
Phenotype Gene Chromosome Reference
Primary AF
Lone AF, high ventricular rate unknown unknown (13)
Lone AF, JB, SSS unknown unknown (13)
Lone AF, high ventricular rate unknown 10q22-q24 (12)
Lone AF KCNQ1 11p15.5 (16)
Long QT syndrome, SB, AF unknown 4q25-q27 (7)
AF associated with structural heart disease
DCM, AF, conduction disease, muscular dystrophy Lamin A/C 1q21.2 (6)
Emerin Xq28 (7)
DCM, conduction disease, AF unknown 3p22 (10)
WPW w/wo HCM AF PRKAG2 7q36 (8)
HCM, AF MYH7 14q12 (9)
Left ventricular noncompaction -dystrobrevin 18q12.1-q12.2 (7)
Glycogen storage disease IIb LAMP2 Xp24 (7)
Methionine adenosyltransferase deficiency (MAT) MATA1 10q22 (7)
Familial amyloidosis unknown unknown (14)
Mitral valve prolapse unknown 16p11 (7)
Holt-Oram syndrome TBX5 12q24.1 (7)
AF associated with precipitating factors
Coronary artery disease, pericarditis, valvular heart
disease, congenital heart disease, hypertension,
ventricular dysfunction, thyrotoxic heart disease
KCNE1 S38G* Xx21q22.1-q22.2 (15)
*Polymorphism.
AF  atrial fibrillation; DCM  dilated cardiomyopathy; HCM  hypertrophic cardiomyopathy; JB  junctional rhythm;
SB  sinus bradycardia; SSS  sick sinus syndrome; WPW  Wolff-Parkinson-White pre-excitation syndrome.
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tional significance and the electrophysiologic consequences
of the genetic variation are currently unknown. However,
these findings may provide new insights into the pathophys-
iology and potential treatment of the disease.
The second recent study reports the discovery of the first
gene causing lone AF in a Chinese family with autosomal
dominant transmission (16). Not surprisingly, the disease-
gene (KCNQ1 or KvLQT1) encodes the alpha subunit of
the cardiac IKs potassium channel, as well as the KCNQ1/
KCNE2 and KCNQ1/KCNE3 potassium channels, and is
again involved in atrial repolarization. The disease-causing
mutation (S140G) causes a gain-of-function of the
KCNQ1/KCNE1 and KCNQ1/KCNE2 channels, reduc-
ing the action potential duration and the effective refractory
period, therefore inducing a mechanism able to initiate and
maintain AF. Interestingly, different mutations in the same
gene were found to cause loss-of-function and lead to long
QT syndrome (17). The phenotypic heterogeneity of
KCNQ1 is not surprising, as it is also observed in other ion
channel diseases. For example, as mentioned before, differ-
ent mutations in SCN5A may cause long QT, conduction
defects, and Brugada syndrome (14). The finding of major
involvement of K channels in the etiology of AF offers the
opportunity to develop novel therapeutic strategies, such as
IKs blockers.
Role of the changes in gene expression (electrical remod-
eling) in maintaining AF. A well-known principle in
human genetics states that every phenotype is determined
by the interaction of three factors: major genes with a strong
effect; several weak genes with a modifier effect, leading to
susceptibility or protection; and the environment. In the
case of AF phenotype, recent studies have shown that
changes in gene expression (the molecular environment) are
critical in maintaining the arrhythmia and transforming
paroxysmal episodes in a chronic irreversible condition.
Once initiated, AF induces an alteration of the electrophys-
iological properties that favors induction and maintenance
of the arrhythmia—a process called “electrical remodeling”
(18). The rapid atrial rate causes a progressive intracellular
Ca2 loading, which threatens cell viability and induces a
final common pathway of defensive responses in the cell.
These include transcriptional down-regulation of the Ca2
channel (ICa), decrease of the Ca
2 current, alteration in
both the inward and outward K currents, and decrease of
the action potential and of the refractory period that
eventually promotes and maintains AF by multiple-circuit
re-entry. Furthermore, the Ca2 overload and the decreased
Ca2 exchange induce cellular myolysis and activation of
the fetal gene program leading to structural remodeling, and
reduce atrial contraction (atrial stunning) contributing to
blood stasis and thromboembolism. Overall, the atrial ionic
remodeling follows pathways very similar to those in ven-
tricular remodeling in heart failure, suggesting a common
underlying mechanism (19).
The advances in understanding the remodeling process
may have important clinical implications in terms of pre-
vention (such as early cardioversion, implantable atrial
defibrillator, and preventive atrial pacing methods) and
therapies to drive reverse remodeling (5). This new under-
standing will clearly influence future investigations of genes
involved in the remodeling pathways that may cause or
modulate AF.
Conclusions. The new insights on genes and genotype/
phenotype correlations involved in AF have impressively
increased our understanding of the pathophysiological
mechanisms leading to arrhythmia. The new knowledge
supports investigations about novel disease genes, their
interactions with remodeling mechanisms, and potential
therapies to treat AF at the ion channel and cellular levels.
In this process, unraveling the clinical and molecular genet-
ics of AF has a central role that may provide new insights
into the structural and electrical phenotypes resulting from
genetic mutations. Eventually genomic information in AF
patients will impact the optimal approach to care, from
prevention and diagnosis to therapy and counseling. At that
point systematic genetic screening will become standard in
the management of familial AF in clinical practice.
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